“Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two primary doses.”
This seems to make third dosing sound like a pretty good idea, definitely 6 months after the second dose, and probably as early as 3-4 months after the second dose (when the Israel data shows efficacy starting to decline). Curious if others disagree!
That data is very helpful and clear, thanks for sharing! Pfizer has some initial findings that suggest to me that a third dose would fix the declining efficacy issue: https://cdn.pfizer.com/pfizercom/2021-07/Delta_Variant_Study_Press_Statement_Final_7.8.21.pdf?IPpR1xZjlwvaUMQ9sRn2FkePcBiRPGqw
“Pfizer and BioNTech have seen encouraging data in the ongoing booster trial of a third dose of the current BNT162b2 vaccine. Initial data from the study demonstrate that a booster dose given 6 months after the second dose has a consistent tolerability profile while eliciting high neutralization titers against the wild type and the Beta variant, which are 5 to 10 times higher than after two primary doses.”
This seems to make third dosing sound like a pretty good idea, definitely 6 months after the second dose, and probably as early as 3-4 months after the second dose (when the Israel data shows efficacy starting to decline). Curious if others disagree!